immunity News and Research

RSS

Study confirms long-term effectiveness of HPV vaccination

Human papillomavirus (HPV) vaccination is associated with a significantly reduced risk of invasive cervical cancer, with no indication of waning protection up to 18 years after vaccination, finds a study from Sweden published by The BMJ today.

25 Feb 2026

Early-life immune system differences drive childhood eczema risk

A team of researchers at the Icahn School of Medicine at Mount Sinai, Weill Cornell Medicine, and other institutions have uncovered a key biological explanation for why eczema so often starts in childhood.

25 Feb 2026

ARPA-H-funded PROSPR program focuses on the biological hallmarks of aging

Columbia University Mailman School of Public Health has received an award as part of the PROactive Solutions for Prolonging Resilience (PROSPR) program within the Advanced Research Projects Agency for Health (ARPA-H) to accelerate research on the biological hallmarks of aging.

24 Feb 2026

US measles and pertussis outbreaks expose policy failures, not just vaccine hesitancy

A recent commentary argues that US measles and pertussis outbreaks are not simply the result of vaccine hesitancy but reflect weakened immunization policies, permissive exemptions, and underfunded public health systems. The authors contend that policy environments determine whether pockets of low coverage escalate into large-scale, preventable outbreaks.

24 Feb 2026

Viral RNA modifications trigger celiac inflammation

An EHU study indicates that a drug already approved for use in humans could help to reduce the inflammation associated with celiac disease.

24 Feb 2026

Study links team creativity to lower clinician burnout

A new study from the Columbia University Mailman School of Public Health identifies team creativity as a powerful, measurable driver of well-being and effectiveness in primary care.

23 Feb 2026

Novel antimicrobial peptides from dromedary camels offer hope against antibiotic resistance

Antimicrobial resistance poses a growing global health crisis, with few new antibiotics in development.

22 Feb 2026

Low-fiber diets quickly impair emotional memory in aging brains

Past studies in animals have shown that a highly processed diet is linked to memory problems and inflammation in the aged brain – and the effect can happen fast, after just three days of poor eating.

19 Feb 2026

Genome sequencing data reveals new insights into Epstein-Barr virus immunity

The Epstein-Barr virus (EBV) can cause certain types of cancer or autoimmune diseases, but how the body controls this common viral infection is largely unknown.

19 Feb 2026

Precision mRNA vaccine strategy shows early promise for improving TNBC relapse risk

An individualized neoantigen mRNA vaccine was tested in patients with early-stage triple-negative breast cancer and showed feasibility, safety, and strong T cell immune responses. Long-term follow-up suggested durable immune memory with encouraging relapse-free outcomes, though controlled trials are needed to confirm clinical benefit.

19 Feb 2026

Study reveals coffee triggers distinct cytokine responses compared with pure caffeine

A randomized crossover pilot study in healthy adults found that coffee and isolated caffeine produce distinct short-term immune responses despite equivalent caffeine doses. The results suggest non-caffeine coffee compounds may influence cytokine activity and caffeine metabolism, although findings remain preliminary due to the small sample size.

19 Feb 2026

Developmental ANGPTL4 deficiency protects mice from colitis and tumors

A novel study using a mouse model has found that the absence of the angiopoietin-like 4 (ANGPTL4) protein during development triggers a long-lasting reprogramming of the immune system that protects against intestinal inflammation.

18 Feb 2026

New study uncovers link between pediatric OSA and higher risk of viral infections

A five-year study has revealed that children with sleep apnea are twice as likely to contract the flu or COVID-19, regardless of their age or weight.

17 Feb 2026

Chronic inflammation shapes cancer progression and immunotherapy response

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

16 Feb 2026

Aptar Pharma’s intranasal solutions power CastleVax Phase II clinical trials for next-gen COVID-19 vaccine

In a significant step forward for mucosal immunity, Aptar Pharma has announced that its innovative nasal delivery systems are being utilized in CastleVax’s Phase II clinical trial for CVAX-01, an intranasal COVID-19 vaccine candidate.

From Hanson Wade Group - 4th Nasal Formulation & Delivery Summit 16 Feb 2026

Innate immune priming may evolve into a broadly applicable infection-prevention strategy

Secondary infections caused by bacteria or viruses during hospital care remain a long-standing global challenge, despite advances in modern medicine.

16 Feb 2026

Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation

Intranasal boosting after prior intramuscular COVID vaccination induced strong mucosal IgA responses in a small human cohort. These antibodies showed markedly enhanced neutralising activity against Omicron variants and evidence of immune memory reprogramming toward mucosal protection.

15 Feb 2026

Universal famine thresholds may mask unfolding starvation

Recent global crises have exposed the limits of a universal mortality threshold for declaring famine-an approach that can obscure how famine actually unfolds across different populations.

13 Feb 2026

Antibody feedback reshapes B cell selection during immune response

A collaborative study published in Immunity from the Batista Lab and Liu Lab at the Ragon Institute, together with the Schief Lab at Scripps Research Institute, has uncovered a previously unrecognized mechanism that shapes how immune cells are selected during an immune response.

13 Feb 2026

SLAMF6 discovery offers hope for non-responding cancer patients

Cancer researchers working on immunotherapies have made a big discovery: SLAMF6, a molecule on the surface of immune cells that prevents T cells from effectively attacking tumors – and, in mice, they've found a way to neutralize it.

12 Feb 2026

immunity News and Research

Study confirms long-term effectiveness of HPV vaccination

Early-life immune system differences drive childhood eczema risk

ARPA-H-funded PROSPR program focuses on the biological hallmarks of aging

US measles and pertussis outbreaks expose policy failures, not just vaccine hesitancy

Viral RNA modifications trigger celiac inflammation

Study links team creativity to lower clinician burnout

Novel antimicrobial peptides from dromedary camels offer hope against antibiotic resistance

Low-fiber diets quickly impair emotional memory in aging brains

Genome sequencing data reveals new insights into Epstein-Barr virus immunity

Precision mRNA vaccine strategy shows early promise for improving TNBC relapse risk

Study reveals coffee triggers distinct cytokine responses compared with pure caffeine

Developmental ANGPTL4 deficiency protects mice from colitis and tumors

New study uncovers link between pediatric OSA and higher risk of viral infections

Chronic inflammation shapes cancer progression and immunotherapy response

Aptar Pharma’s intranasal solutions power CastleVax Phase II clinical trials for next-gen COVID-19 vaccine

Innate immune priming may evolve into a broadly applicable infection-prevention strategy

Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation

Universal famine thresholds may mask unfolding starvation

Antibody feedback reshapes B cell selection during immune response

SLAMF6 discovery offers hope for non-responding cancer patients

Industry Focus eBook - Cell biology (5th edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News